Sale!

Comprehensive Dermatologic Drug Therapy 4th edition by Stephen Wolverton, Jashin Wu ISBN 0323612547 9780323612548

Original price was: $70.00.Current price is: $35.00.

Instant download Comprehensive Dermatologic Drug Therapy after payment

SKU: EB_96396 Category: Tags: , ,

Comprehensive Dermatologic Drug Therapy 4th edition by Stephen Wolverton, Jashin Wu – Ebook PDF Instant Download/Delivery: 0323612547, 9780323612548
Full download Comprehensive Dermatologic Drug Therapy 4th edition after payment


Product details:

ISBN 10: 0323612547
ISBN 13: 9780323612548
Author: Stephen Wolverton, Jashin Wu

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you’re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today’s full spectrum of topical, intralesional, and systemic drugs. You’ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.

  • Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions.
  • Covers the best uses for new biologic therapeutics.
  • Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors.
  • Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
  • Features a highly detailed, disease-specific index, as well as purchase information for major drugs.
  • Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.
  • Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Comprehensive Dermatologic Drug Therapy 4th Table of contents:

Part I. Introduction

1. Basic Principles of Pharmacology

  • Introduction

  • Pharmacokinetics—Part I (Tables 1.2 and 1.3)

  • Pharmacodynamics (The Drug Produces the Desired Pharmacologic Effect)

  • Pharmacokinetics—Part II

  • Percutaneous Absorption

  • Summary

2. Principles for Maximizing the Safety of Dermatologic Drug Therapy

  • Introduction

  • Anticipation

  • Prevention

  • Diagnosis

  • Management

  • Parting Thoughts

3. Polymorphisms: Why Individual Drug Responses Vary

  • Introduction

  • Evaluating the Patient

  • Factors That Influence Medication Effects (Including Adverse Effects)

  • Drug Metabolism—Phase I Reactions

  • Drug Metabolism—Phase II Reactions (TABLE 3.9)

  • Tests for Genetic Polymorphisms and Clinical Significance

  • Pharmacogenomic Databases

  • Conclusions and Future Directions

4. Adherence to Drug Therapy

  • Introduction

  • Measures of Adherence

  • The Magnitude of Poor Adherence in Dermatology

  • Factors that Influence Adherence Behavior

  • Strategies to Improve Adherence Behavior

  • Conclusions

5. Medical Decision Making

  • Introduction

  • Patient Individualization and Prioritization (Box 5.1)

  • Medical Decision Making (Box 5.2)

  • Causation Determination (Box 5.3)

  • Evaluating the Medical Literature (Box 5.4)

  • Interpretation of Medical Literature (Box 5.5)

  • Prescriber Responsibilities (Box 5.7)

  • Longitudinal Patient Care Decisions (Box 5.8)

  • Decision-Making Realities (Box 5.9)

Part II. Important Drug Regulatory Issues

6. The FDA Drug Approval Process

  • Introduction

  • Federal Legislation for Drug Safety and Efficacy

  • Phase I to IV Testing

  • US Food and Drug Administration Advisory Panels

  • Off-Label Drug Use

  • Generic Drugs

  • Special Drug Approval Categories

  • Related Issues

7. Pharmacovigilance: Verifying that Drugs Remain Safe

  • Introduction

  • Summary

8. Drugs Taken Off the Market: Important Lessons Learned

  • Introduction

  • Presentation of Risk–Benefit in Labeling

  • Product Label ‘Lifecycle’ Changes

  • Risks and Benefits: US Food and Drug Administration Safety Information

  • Drug Withdrawal

Part III. Systemic Drugs for Infectious Diseases

9. Systemic Antibacterial Agents

  • Introduction

  • Penicillins

  • Cephalosporins

  • β-Lactam and β-Lactamase Inhibitor Combinations

  • Other Systemic Antibacterials that Inhibit Cell Wall Synthesis

  • Macrolides

  • Fluoroquinolones

  • Tetracyclines

  • Rifampin and Other Rifamycins

  • Folate Synthesis Inhibitors

  • Lincosamides

  • Oxazolidinones

  • Special Topics

10. Systemic Antifungal Agents

  • Introduction

  • Mechanism of Action

  • Conclusion

11. Systemic Antiviral Agents

  • Introduction

  • Drugs for Human Herpes Virus Infections

  • Drugs for Human Immunodeficiency Virus Infections

  • Therapeutic Guidelines—Drugs for Human Immunodeficiency Virus Infections

  • Summary

12. Systemic Antiparasitic Agents

  • Ivermectin

  • Albendazole

  • Thiabendazole

  • Alternative Agents—Doxycycline As Antiparasitic Agent

Part IV. Systemic Immunomodulatory Drugs

13. Systemic Corticosteroids

  • Systemic Corticosteroids

  • Pharmacology (Table 13.1)

  • Clinical Use

14. Methotrexate

  • Introduction

  • Pharmacology

  • Clinical use

15. Azathioprine

  • Introduction

  • Pharmacology

  • Clinical Use

  • Summary

16. Mycophenolates

  • Introduction

  • Pharmacology

  • Mechanisms of Action

  • Clinical Use

  • Off-Label Dermatologic Uses

  • Immunobullous Disease

  • Autoimmune Connective Tissue Disease

17. Cyclosporine

  • Introduction

  • Summary

18. Phosphodiesterase-4 and Janus Kinase Inhibitors

  • Introduction

  • Small Molecule Treatments

  • Mechanism of Action of Phosphodiesterase 4 Inhibition

  • Phosphodiesterase 4 Inhibitor Therapy

  • Janus Kinase Inhibitors

  • Conclusion

19. Cytotoxic Agents

  • Introduction

  • Major Subcategories of Cytotoxic Agents and the Cell Cycle

  • Patient Education Issues

  • Antimetabolites

  • Alkylating Agents

20. Dapsone

  • Introduction

  • Pharmacology

  • Clinical Use

21. Antimalarial Agents

  • Introduction

  • Pharmacology

  • Clinical Use

  • Other Potential Benefits

  • Monitoring Guidelines

  • Drug Interactions

  • Therapeutic Guidelines

22. Systemic Retinoids

  • Introduction and Historical Perspective

  • Pharmacology

  • Clinical Use

Part V. Drugs Used in Conjunction with UV or Visible Light

23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

  • Introduction

  • Psoralen Plus Ultraviolet A Photochemotherapy

  • Narrow-Band Ultraviolet B Phototherapy

  • Targeted Phototherapy

  • Uva-1 Phototherapy

24. Extracorporeal Photochemotherapy (Photopheresis)

  • Introduction

  • Treatment Delivery and Considerations

  • Pharmacology

  • Clinical Use

25. Photodynamic Therapy

  • Introduction

  • Pharmacology

  • Clinical Use

Part VI. Biologic Therapeutics

26. Tumor Necrosis Factor Inhibitors

  • Introduction—Psoriasis Pathogenesis

  • Etanercept

  • Infliximab

  • Adalimumab

  • Certolizumab Pegol

27. Interleukin 12/23 Inhibitors

  • Introduction

  • Monoclonal Antibody Treatments

  • Interleukin-12/23 Therapy – Ustekinumab

  • Conclusions

28. Interleukin 17 Inhibitors

  • Introduction

  • Secukinumab

  • Ixekizumab

  • Brodalumab

  • Common Adverse Events Among All IL-17 Inhibitors

  • Summary

29. Interleukin 23 Inhibitors

  • Introduction

  • US Food and Drug Administration Approval

  • Guselkumab

  • Tildrakizumab

  • Risankizumab

  • Future IL-23 Inhibitors for Psoriasis

  • Conclusion

30. Rituximab

  • Introduction

31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

  • Dupilumab

  • Omalizumab

  • Other Biologic Therapies in Development

Part VII. Miscellaneous Systemic Drugs

32. Antihistamines

  • Historical Overview

  • First-Generation Antihistamines

  • Second-Generation H1 Antihistamines

  • H1 Antihistamine in Pregnancy and Lactation

  • H2 Antihistamines

  • Tolerance (Tachyphylaxis and Subsensitivity)

  • Oral and Topical Doxepin

  • Antihistamine Therapy of Chronic Urticaria and Angioedema

  • Antihistamines for Atopic Dermatitis

33. Vasoactive and Antiplatelet Agents

  • Pathophysiology Involving Cutaneous Vasculature

  • Calcium Channel Blockers

  • β-Blockers

  • Aspirin

  • Dipyridamole (Box 33.4)

  • Pentoxifylline (Box 33.5)

  • Nitric Oxide Donors

  • Phosphodiesterase-5 Inhibitors

  • Iloprost

  • Antiangiogenesis Agents

34. Antiandrogens and Androgen Inhibitors

  • Introduction

  • Physiologic Role of Androgens

  • Antiandrogens

  • Androgen Inhibitors

  • Hormone Preparations

  • Gonadotropin-Releasing Hormone Analogs

  • Herbal and Experimental Therapies

Part VIII. Topical Drugs for Infectious Diseases

41. Topical Antibacterial Agents

  • Introduction

  • Drugs Used for Wound Care and Minor Topical Bacterial Infections

  • Drugs Used for Acne and Rosacea

  • Antiseptics

42. Topical Antifungal Agents

  • Introduction

  • Polyenes

  • Azoles

  • Allylamines and Benzylamines

  • Other Topical Antifungals

  • Comparative Studies

43. Topical and Intralesional Antiviral Agents

  • Introduction

  • Viricidal Drugs

  • Immune-Enhancing Drugs

  • Cytodestructive Drugs

44. Topical Antiparasitic Agents

  • Introduction

  • Permethrin and Pyrethrins

  • Ivermectin—Topical (Table 44.3)

  • Malathion (Table 44.4)

  • Spinosad (Table 44.5)

  • Crotamiton

  • Benzyl Benzoate

  • Precipitated Sulfur

  • Lindane

  • Melaleuca Alternifolia (Tea Tree) Oil

  • Nonpharmacologic Therapy for Head Lice

  • Miscellaneous Antiparasitic Agents

Part IX. Topical Immunomodulatory Drugs

45. Topical Corticosteroids

  • Introduction

  • Pharmacology

  • Clinical Use

  • Adverse Effects—Systemic

  • Adverse Effects—Local

  • Therapeutic Guidelines

46. Topical Retinoids

  • Introduction

  • Pharmacology

  • Clinical Use

47. Topical and Intralesional Chemotherapeutic Agents

  • Introduction

  • Topical Chemotherapeutic Agents

  • Intralesional Chemotherapeutic Agents

48. Topical Calcineurin Inhibitors

  • Introduction

  • Tacrolimus

  • Pimecrolimus

49. Topical Vitamin D3

  • Introduction

  • Pharmacology

  • Vitamin D Analogs

  • Calcipotriene—Clinical Use

Part X. Miscellaneous Topical Drugs

50. Sunscreens

  • Introduction

  • Sunscreen Options

  • Clinical Use

  • Summary

51. Therapeutic Shampoos

  • Introduction

  • Dermatoses Involving the Scalp

  • Clinical Use

  • Therapeutic Guidelines

  • Summary

52. α-Hydroxy Acids

  • Introduction

  • Pharmacology

  • Clinical Use

  • Formulations and Bioavailability

  • Safety and Adverse Effects

  • Summary

Part XI. Injectable and Mucosal Routes of Drug Administration

58. Local Anesthetics

  • Introduction

  • Injectable Local Anesthetics

  • Topical Anesthetics

  • Coinjectable Vasoconstrictors

  • Other Agents with Local Anesthetic Effects

59. Injectable Dermal and Subcutaneous Fillers

  • Introduction

  • Categories of Dermal Fillers

  • Autologous Human Fibroblasts

  • Fillers on the Horizon

  • Adverse Effects

60. Botulinum Toxin Injections

  • Introduction and History

  • Conclusions

Part XII. Major Adverse Effects From Systemic Drugs

62. Hepatotoxicity of Dermatologic Drug Therapy

  • Introduction

  • The Liver and Drug Metabolism

  • Mechanisms of Drug Hepatotoxicity

  • Risk Factors for Drug Hepatotoxicity

  • Drug Information Dissemination Issues

  • Classification Systems

  • Drug Etiologies

  • Diagnosis

  • Management

  • Looking to the Future—Lessons from the Past

Part XIII. Special Pharmacology and Therapeutics Topics

68. Informed Consent and Risk Management

  • Introduction

  • Historical Perspective

  • Ethical Perspective

  • Basic Legal Principles

  • Components of Informed Consent

  • Systemic Drugs and Informed Consent

  • Optimizing Patient Understanding

  • Exceptions to the Informed Consent Requirements

  • Medicolegal Risk Management

  • Dermatology Malpractice

  • Summary

69. Compounding in Dermatology

  • Introduction

  • The Compounding Triad

  • Developing a Stable Compounding Formula

  • Properly Write the Prescription

  • Monitor the Patient

  • Summary

70. Dermatologic Drug Therapy in Children

  • Introduction

  • Pediatric Considerations for Commonly Used Medications

  • Systemic Retinoids

  • Systemic Immunosuppressive Therapies

Appendix I. Core Questions for Understanding Systemic Dermatologic Drugs
Appendix II. The Most Potentially Serious Drug Interactions
Index

People also search for Comprehensive Dermatologic Drug Therapy 4th:

comprehensive dermatologic drug therapy. fourth edition

comprehensive dermatologic drug therapy book

comprehensive dermatologic drug therapy pdf free download

comprehensive dermatologic drug therapy 4th edition pdf

ca comprehensive dermatology photos

Tags: Stephen Wolverton, Jashin Wu, Comprehensive Dermatologic, Drug Therapy